<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511263</url>
  </required_header>
  <id_info>
    <org_study_id>AC-006-IT</org_study_id>
    <nct_id>NCT01511263</nct_id>
  </id_info>
  <brief_title>Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis</brief_title>
  <acronym>EpiCardiAL</acronym>
  <official_title>A Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a proportion of patients with AL amyloidosis there is no improvement of cardiac function
      despite hematologic response to treatment. The aim of the study is to assess whether
      treatment with EGCG increases the rate of cardiac response in patients with AL amyloidosis
      who completed chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase II open-label randomized trial. Patients with AL amyloidosis and cardiac
      involvement who have achieved at least partial hematologic response after chemotherapy will
      be randomized to receive standard supportive therapy (SST) or SST plus Epigallocatechin
      gallate (EGCG). After giving written informed consent, the patients will be evaluated for
      eligibility. Briefly, the subjects with a biopsy-proven diagnosis of AL amyloidosis who
      achieved at least partial response after chemotherapy, who are not planned to receive further
      chemotherapy and who have significant cardiac dysfunction will be considered eligible. The
      patients will be stratified according to the quality of hematologic response and to the
      severity of cardiac involvement. Following stratification, the patients will be randomized to
      receive SST or SST plus EGCG. The study comprises 3 periods: screening (including
      stratification and randomization), treatment (with evaluations of response every 2 months)
      followed by the end-of-treatment evaluation and follow-up. Therapy will continue for up to 1
      year. After treatment patients will be followed for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac response</measure>
    <time_frame>6 months</time_frame>
    <description>The primary objective is to assess whether treatment with EGCG increases the rate of cardiac response following chemotherapy in patients with AL amyloidosis. The primary endpoint is cardiac response at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary objectives are to assess the safety of EGCG in cardiac AL amyloidosis, to determine whether EGCG can prevent or delay cardiac progression and to compare survival of patients receiving EGCG compared to subjects receiving SST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiac progression</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary objectives are to assess the safety of EGCG in cardiac AL amyloidosis, to determine whether EGCG can prevent or delay cardiac progression and to compare survival of patients receiving EGCG compared to subjects receiving SST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cardiac progression</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary objectives are to assess the safety of EGCG in cardiac AL amyloidosis, to determine whether EGCG can prevent or delay cardiac progression and to compare survival of patients receiving EGCG compared to subjects receiving SST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiac events</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary objectives are to assess the safety of EGCG in cardiac AL amyloidosis, to determine whether EGCG can prevent or delay cardiac progression and to compare survival of patients receiving EGCG compared to subjects receiving SST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cardiac events</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary objectives are to assess the safety of EGCG in cardiac AL amyloidosis, to determine whether EGCG can prevent or delay cardiac progression and to compare survival of patients receiving EGCG compared to subjects receiving SST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months</time_frame>
    <description>The secondary objectives are to assess the safety of EGCG in cardiac AL amyloidosis, to determine whether EGCG can prevent or delay cardiac progression and to compare survival of patients receiving EGCG compared to subjects receiving SST.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Primary Amyloidosis of Light Chain Type</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)</intervention_name>
    <description>Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG</intervention_name>
    <description>Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
EGCG, 675 mg/day, oral, for one year.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AL amyloidosis.

          -  Age ≥18 years.

          -  The patients must have been treated for AL amyloidosis attaining hematologic response.

          -  Evidence of cardiac involvement at echocardiography (mean left ventricular wall
             thickness &gt;12 mm in the absence of other causes).

          -  NT-proBNP ≥650 ng/L

        Exclusion Criteria:

          -  Non-AL (e.g. familial, senile) amyloidosis.

          -  Concomitant non-amyloid related clinically significant cardiac diseases.

          -  Need of further chemotherapy for AL amyloidosis.

          -  Estimated glomerular filtration rate (eGFR) &lt;30 mL/min per 1.73 m2.

          -  Uncontrolled infection.

          -  Inability to give informed consent.

          -  Previous or ongoing psychiatric illness (excluding reactive depression).

          -  Pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.amiloidosi.it/</url>
  </link>
  <reference>
    <citation>Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751-7.</citation>
    <PMID>15365071</PMID>
  </reference>
  <reference>
    <citation>Hunstein W. Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood. 2007 Sep 15;110(6):2216.</citation>
    <PMID>17785589</PMID>
  </reference>
  <reference>
    <citation>Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol. 2010 Aug;99(8):483-90. doi: 10.1007/s00392-010-0142-x. Epub 2010 Mar 10.</citation>
    <PMID>20221615</PMID>
  </reference>
  <reference>
    <citation>Mereles D, Wanker EE, Katus HA. Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol. 2008 May;97(5):341-4. doi: 10.1007/s00392-008-0649-6. Epub 2008 Mar 3.</citation>
    <PMID>18317666</PMID>
  </reference>
  <reference>
    <citation>Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol. 2008 Jun;19 Suppl 4:iv63-6. doi: 10.1093/annonc/mdn200. Review.</citation>
    <PMID>18519408</PMID>
  </reference>
  <reference>
    <citation>Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Bragotti LZ, Obici L, Moratti R, Melzi d'Eril GV, Merlini G. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010 Nov 4;116(18):3426-30. doi: 10.1182/blood-2010-05-286567. Epub 2010 Jul 19.</citation>
    <PMID>20644111</PMID>
  </reference>
  <reference>
    <citation>Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003 May 20;107(19):2440-5. Epub 2003 Apr 28.</citation>
    <PMID>12719281</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Giampaolo Merlini</investigator_full_name>
    <investigator_title>Director, Amyloidosis Research and Treatment Center</investigator_title>
  </responsible_party>
  <keyword>Epigallocatechin gallate</keyword>
  <keyword>AL amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

